ZK 158252

Drug Profile

ZK 158252

Latest Information Update: 15 Dec 2000

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Class Anti-inflammatories; Antipsoriatics
  • Mechanism of Action Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psoriasis

Most Recent Events

  • 15 Dec 2000 No-Development-Reported for Psoriasis (Topical)
  • 28 Jan 1998 New profile
  • 28 Jan 1998 Investigation in Psoriasis (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top